BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1082 related articles for article (PubMed ID: 28147244)

  • 21. Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells.
    Harder BG; Peng S; Sereduk CP; Sodoma AM; Kitange GJ; Loftus JC; Sarkaria JN; Tran NL
    Mol Med; 2019 Nov; 25(1):49. PubMed ID: 31726966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.
    van Nifterik KA; van den Berg J; Stalpers LJ; Lafleur MV; Leenstra S; Slotman BJ; Hulsebos TJ; Sminia P
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1246-53. PubMed ID: 17967314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O
    Chang KY; Hsu TI; Hsu CC; Tsai SY; Liu JJ; Chou SW; Liu MS; Liou JP; Ko CY; Chen KY; Hung JJ; Chang WC; Chuang CK; Kao TJ; Chuang JY
    Redox Biol; 2017 Oct; 13():655-664. PubMed ID: 28822335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells.
    Wong ST; Zhang XQ; Zhuang JT; Chan HL; Li CH; Leung GK
    Anticancer Res; 2012 Jul; 32(7):2835-41. PubMed ID: 22753745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
    Minea RO; Duc TC; Swenson SD; Cho HY; Huang M; Hartman H; Hofman FM; Schönthal AH; Chen TC
    PLoS One; 2020; 15(9):e0238238. PubMed ID: 32881880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells.
    Goker Bagca B; Ozates NP; Asik A; Caglar HO; Gunduz C; Biray Avci C
    Biochem Biophys Res Commun; 2020 Dec; 533(4):1497-1504. PubMed ID: 33109342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
    Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R
    Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells.
    Cheng Q; Ma X; Cao H; Chen Z; Wan X; Chen R; Peng R; Huang J; Jiang B
    Mol Med Rep; 2017 Feb; 15(2):597-604. PubMed ID: 28035389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells.
    De Salvo M; Maresca G; D'agnano I; Marchese R; Stigliano A; Gagliassi R; Brunetti E; Raza GH; De Paula U; Bucci B
    Int J Radiat Biol; 2011 May; 87(5):518-33. PubMed ID: 21405945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway.
    Chen L; Han L; Shi Z; Zhang K; Liu Y; Zheng Y; Jiang T; Pu P; Jiang C; Kang C
    Mol Med Rep; 2012 Feb; 5(2):575-9. PubMed ID: 22086271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide.
    Murphy SF; Varghese RT; Lamouille S; Guo S; Pridham KJ; Kanabur P; Osimani AM; Sharma S; Jourdan J; Rodgers CM; Simonds GR; Gourdie RG; Sheng Z
    Cancer Res; 2016 Jan; 76(1):139-49. PubMed ID: 26542214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
    Liu T; Li A; Xu Y; Xin Y
    Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function.
    Chen L; Li X; Liu L; Yu B; Xue Y; Liu Y
    Oncol Rep; 2015 Mar; 33(3):1465-74. PubMed ID: 25585997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
    Huang H; Lin H; Zhang X; Li J
    Oncol Rep; 2012 Jun; 27(6):2050-6. PubMed ID: 22426504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity.
    Chen PH; Shen WL; Shih CM; Ho KH; Cheng CH; Lin CW; Lee CC; Liu AJ; Chen KC
    Neuropharmacology; 2017 Apr; 116():300-314. PubMed ID: 27986595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide.
    Weyhenmeyer BC; Noonan J; Würstle ML; Lincoln FA; Johnston G; Rehm M; Murphy BM
    Oncotarget; 2016 Sep; 7(38):61295-61311. PubMed ID: 27494880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.